ProCE Banner Activity

The Role of First-Generation vs Second-Generation PI3K Inhibitors in CLL

Clinical Thought
Promising data have been reported for the next-generation PI3K inhibitors umbralisib and duvelisib. Here’s my take on when to use which PI3K inhibitor in CLL.

Released: September 13, 2018

Expiration: September 12, 2019

No longer available for credit.

Share

Faculty

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Acerta Pharma AstraZeneca Group

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Celgene, Genentech, Gilead Sciences, Janssen, and Pharmacyclics.